Cetuximab (Erbitux) for metastatic colorectal cancer
Hayes, Inc.
Record ID 32011000881
English
Authors' objectives:
Cetuximab (Erbitux®; ImClone Systems Inc., Bristol-Myers Squibb) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is used, alone or in combination with chemotherapy, for the treatment of metastatic colorectal carcinoma (mCRC).
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=11873
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Colorectal Neoplasms
- Cetuximab
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.